Prognostic impact of circulating tumor cells in oligometastatic hormone-sensitive prostate cancer following metastasis-directed therapy.
Authors: Soha Bazyar, Philip Sutera, Ryan Phillips, Mathew Pierre Deek, Noura Radwan, Catherine Handy Marshall, Mark V. Mishra, Zaker Hamid Rana, Jason K. Molitoris, Young Kwok, Santosh Gupta, Alisa Tubbs, Rick Wenstrup, Theodore L. DeWeese, Daniel Y. Song, Felix Y Feng, Kenneth J. Pienta, Emmanuel S. Antonarakis, Ana Ponce Kiess, Phuoc T. Tran
Journal: Journal of Clinical Oncology (2023)

199 Background: Contained within the spectrum of metastatic cancer is an oligometastatic state where metastases are limited in number. Recent prospective data have shown that metastasis directed therapy (MDT) can alter the natural history of oligometastatic disease. In hormone-sensitive prostate cancer (HSPC), the positive clinical effect of MDT has been observed by the phase II STOMP and ORIOLE trials. Circulating tumor cells (CTCs) are a likely origin of the formation of macroscopic metastases. CTCs thus may provide an approach for identifying subgroups of patients with oligometastatic HSPC (oligoHSPC) that would benefit most from MDT. Our main goal was to evaluate the association between presence of CTCs at baseline or day 180 with clinical outcomes in the ORIOLE trial. Methods: ORIOLE was a phase II trial randomizing men with recurrent oligoHSPC with 1-3 metastases to observation (Obs) versus stereotactic ablative radiotherapy (SABR) MDT. Blood samples were prospectively collected at baseline and day 180. Progression-free survival (PFS) was a composite endpoint including any of the following: a PSA rise of at least 2 ng/dL and 25% above nadir; radiologic progression by CT, MRI or bone scan (RECIST v1.1); symptomatic progression of disease; initiation of ADT; or death. Patient blood samples were shipped for analysis on Epic Sciences liquid biopsy platform (Epic Sciences, San Diego, CA). Machine learning algorithms identified CTCs and characterized androgen receptor (AR) expression. Comparisons of patient and tumor characteristics between the groups were performed by two-sample t-tests. Survival curves were generated using the Kaplan-Meier method and p-values were calculated using log-rank test. Analysis was performed using SPSS version 28. Results: A total of 82 samples were collected: 70 from the SABR arm (35 baseline and 35 on day 180) and 12 Obs (7 baseline and 5 on day 180). CTCs were detected in 30/42 samples at baseline (71%, AR + = 7) and in 26/40 samples on day 180 (65%, AR + = 9). In the SABR group there was no difference between CTC + versus CTC - and AR + versus AR - groups for PSA evaluated at baseline, day 90 or day 180 or Gleason score. With a median follow-up of 41.7 months, PFS was significantly lower in the patients with AR + versus AR - CTCs at baseline in the SABR arm (p = 0.011, mean PFS: AR + = 9.3 months, AR - = 27.1 months). The mean biochemical failure-free survival was AR + = 12.9 versus AR - = 29.2 months (p = 0.058). Conclusions: Our preliminary results demonstrate an association between AR + CTCs at baseline and Day 180 with clinical outcomes following SABR MDT in oligoHSPC. This is the first report examining baseline and dynamic presence of CTCs in oligoHSPC treated from a prospective randomized trial of SABR. Longer follow-up, further analysis and a greater number of patients are needed for a more comprehensive conclusion.